Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19976 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Francesca Perutelli und 17 weiteren Autor:innen. Beteiligte Einrichtung: University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences,…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high‐risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers. These patients underwent alloHSCT between 2006 and 2021 after failing chemoimmunotherapy (7/7), ibrutinib (5/7) and/or idelalisib (1/7). Of note, 3/7 patients had already received venetoclax‐based therapy before alloHSCT. Post‐allo HSCT venetoclax treatment resulted safe, with adverse events not different from what reported in clinical trials. Importantly, no meaningful impact on graft versus host disease (GvHD) course was observed: 4/7 patients with pre‐existing chronic GvHD had no exacerbation after venetoclax start, and only one patient developed GvHD during venetoclax therapy, that was managed as per standard clinical practice. Concerning efficacy, 5/7 patients presented a clinical response to venetoclax, with two patients achieving an undetectable minimal residual disease. To our knowledge, this is the largest reported series of CLL patients treated with venetoclax after alloHSCT. In these heavily pretreated and high‐risk patients, previous alloHSCT did not compromise the feasibility of venetoclax therapy, that lacked unexpected toxicities and did not exacerbate GvHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Division of Hematology, A.O.U. Città Della Salute e Della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
- Azienda Santa Croce e Carle, Cuneo, Italy.
- Dipartimento di Medicina Traslazionale Università del Piemonte Orientale and S.C.D.U, Ematologia Azienda Ospedaliero Universitaria Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
- Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore Della Carità, Novara, Italy.
ORCID-Profile: Francesca Perutelli, Anna Maria Frustaci, Riccardo Moia, Francesca Maria Quaglia, Luca Laurenti, Marta Coscia
Zitieren
APA
Perutelli, F., Boccellato, E., Montalbano, M. C., Catania, G., Deodato, M., Frustaci, A. M., Innocenti, I., Moia, R., Quaglia, F. M., Quaresmini, G., Rivela, P., Gaidano, G., Krampera, M., Laurenti, L., Rambaldi, A., Bruno, B., Vitale, C., & Coscia, M. (2025). Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.19976
Vancouver
Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, et al. Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2025. doi:10.1111/bjh.19976
BibTeX
@article{Perutelli2025,
author = {Perutelli, Francesca and Boccellato, Elia and Montalbano, Maria Chiara and Catania, Gioacchino and Deodato, Marina and Frustaci, Anna Maria and Innocenti, Idanna and Moia, Riccardo and Quaglia, Francesca Maria and Quaresmini, Giulia and Rivela, Paolo and Gaidano, Gianluca and Krampera, Mauro and Laurenti, Luca and Rambaldi, Alessandro and Bruno, Benedetto and Vitale, Candida and Coscia, Marta},
title = {Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19976}
}
EUVIMED